Ranibizumab Treatment for Age-Related Macular Degeneretion

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyushu University
• Collaborators: Clinical Research Support Center Kyush; Fukuoka University; Kurume University; Novartis; University of Occupational and Environmental Health
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD

• Subjects of either gender age 50 years or older

• Visual acuity better than 0.05 decimal( 20/400 Snellen)

• Signed informed consent form

Exclusion Criteria:

• Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy

• Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye

• Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye

• Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye

• Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors

• The pregnant or lactating woman